Vortioxetine Hydrobromide
Brand name: Trintellix
Rank #142 of 500 drugs by total cost
$113.9M
Total Cost
197,873
Total Claims
$113.9M
Total Cost
7,338
Prescribers
$576
Cost per Claim
7,984
Beneficiaries
242,690
30-Day Fills
$16K
Avg Cost/Provider
27
Avg Claims/Provider
About Vortioxetine Hydrobromide
Vortioxetine Hydrobromide (sold as Trintellix) was prescribed 197,873 times by 7,338 Medicare Part D providers in 2023, costing the program $113.9M. At $576 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 139 | Ambrisentan (Ambrisentan) | $117.7M | 23,927 |
| 140 | Memantine Hcl (Memantine Hcl) | $117.5M | 2,268,098 |
| 141 | Estradiol (Estradiol) | $115.7M | 1,412,386 |
| 142 | Vortioxetine Hydrobromide (Trintellix) | $113.9M | 197,873 |
| 143 | Asfotase Alfa (Strensiq) | $113.8M | 1,142 |
| 144 | Erenumab-Aooe (Aimovig Autoinjector) | $111.9M | 118,455 |
| 145 | Corticotropin (Acthar) | $111.6M | 1,633 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology